Our data provide insights into the potential of EMPA as a novel therapeutic strategy, not only for antidiabetic conditions but also for metabolic diseases, particularly cardiomyopathy in tissues expressing SGLT2. Here, SLC5A2 is linked to cardiomyopathy.